Aclaris Therapeutics (ACRS) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Over five years, PHAT leads with a -79.1% price change compared with -79.8% for ACRS. Phathom Pharmaceuticals is the larger company by market cap ($550.9 million vs $500.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | PHAT |
|---|---|---|
| Share price | $3.40 | $6.81 |
| Market cap | $500.48M | $550.94M |
| 1-day change | -8.11% | +0.44% |
| YTD return | — | -58.95% |
| 1-year return | — | -37.18% |
| 5-year return | -79.77% | -79.05% |
| Forward P/E | — | 6.33 |
| EPS (TTM) | $-0.58 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $18.31 |
| 52-week low | $1.74 | $6.52 |
| Distance from 52-week high | -48.48% | -62.81% |
| Average volume | 2.36M | 1.39M |
| Shares outstanding | 147.20M | 80.90M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
ACRS vs PHAT FAQ
Which is bigger, Aclaris Therapeutics or Phathom Pharmaceuticals?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $550.94M compared with $500.48M for Aclaris Therapeutics (ACRS).
Are Aclaris Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.